-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Raised to $39 at Canaccord
-
-
-
-
-
-
-
Biofrontera (BFRI) Reiterated at Speculative Buy by StoneX as Ameluz Approved For sBCC
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)
-
-
-
-
-
-
-
Belite Bio files Japan drug application for Stargardt disease treatment
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho
-
-
-
-
-
-
-
Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
-
15,819 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

